Arbor Biotechnologies
Biotechnology company pioneering next-generation gene editing technologies and developing genetic medicines using novel CRISPR systems and other genome editing approaches.
Notes
Arbor Biotechnologies is a biotechnology company developing next-generation gene editing technologies and genetic medicines. The company was founded by pioneers in the field of CRISPR and genetic engineering, including Feng Zhang, and focuses on discovering and developing novel genomic editing tools.
Arbor's platform involves discovering new CRISPR systems from metagenomic data and engineering them for therapeutic applications. The company has identified novel families of CRISPR enzymes and other genome engineering tools through computational approaches and experimental validation.
The company's technology platform spans from discovery of new editing systems to therapeutic development, with applications in genetic diseases, cancer, and other conditions.
Team
- David Scott - Co-founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/david-scott
- Winston Yan, Ph.D. - Co-founder & Chief Scientific Officer
- LinkedIn: linkedin.com/in/winstonyan
- Feng Zhang, Ph.D. - Co-founder & Scientific Advisor
- MIT Professor, Broad Institute Core Member
Additional Research Findings
- Co-founded by Feng Zhang, pioneer of CRISPR gene editing
- Discovered novel CRISPR systems including CRISPR-Cas12b and other variants
- Platform for discovering editing tools from metagenomic data
- Cambridge, Massachusetts headquarters
- Focus on genetic medicines and next-generation editing technologies
- Series B funding to advance pipeline
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |